EMMA - Emmaus Life Sciences submits Endari marketing authorization application to Swissmedic

Emmaus Life Sciences ([[EMMA]]) has submitted a Marketing Authorization ((MA)) application for Endari to the Swiss Agency for Therapeutic Products (Swissmedic) in Switzerland.Swissmedic's MA review and approval process typically takes 16 to 18 months.Endari will be available to sickle cell disease patients on an early-access basis during the review and approval process, the company said.Ideogen has partnered up with Emmaus to initiate a managed access program and register the drug to improve access.According to the University of Zurich, there were an estimated 220 people with sickle cell disease in Switzerland in 2017 and that number is expected to increase, Emmaus said.

For further details see:

Emmaus Life Sciences submits Endari marketing authorization application to Swissmedic